Aligos Therapeutics Stock Analysis
Aligos Therapeutics holds a debt-to-equity ratio of 0.098. Aligos Therapeutics' financial risk is the risk to Aligos Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Aligos Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Aligos Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Aligos Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Aligos Therapeutics' stakeholders.
For many companies, including Aligos Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Aligos Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Aligos Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Aligos Therapeutics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Aligos Therapeutics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Aligos Therapeutics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Aligos Therapeutics is said to be less leveraged. If creditors hold a majority of Aligos Therapeutics' assets, the Company is said to be highly leveraged.
Aligos Therapeutics is undervalued with Real Value of 22.16 and Hype Value of 7.01. The main objective of Aligos Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Aligos Therapeutics is worth, separate from its market price. There are two main types of Aligos Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Aligos Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Aligos Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Aligos Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. Aligos Stock Analysis Notes
About 55.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.59. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aligos Therapeutics recorded a loss per share of 13.54. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 19th of August 2024. Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. The company was incorporated in 2018 and is headquartered in South San Francisco, California. Aligos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. For more info on Aligos Therapeutics please contact Dr MBA at 800 466 6059 or go to https://www.aligos.com.Aligos Therapeutics Investment Alerts
| Aligos Therapeutics is not yet fully synchronised with the market data | |
| Aligos Therapeutics had very high historical volatility over the last 90 days | |
| Aligos Therapeutics has some characteristics of a very speculative penny stock | |
| Aligos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.94 M. Net Loss for the year was (131.21 M) with loss before overhead, payroll, taxes, and interest of (65.8 M). | |
| Aligos Therapeutics currently holds about 159.34 M in cash with (80.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. | |
| Roughly 55.0% of the company shares are held by institutions such as insurance companies |
Aligos Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 42.52 M.Aligos Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aligos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aligos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aligos Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aligos Therapeutics Outstanding Bonds
Aligos Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aligos Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aligos bonds can be classified according to their maturity, which is the date when Aligos Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ATDBCN 355 26 JUL 27 Corp BondUS01626PAH91 | View | |
| ATDBCN 295 25 JAN 30 Corp BondUS01626PAM86 | View | |
| ATDBCN 38 25 JAN 50 Corp BondUS01626PAN69 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Aligos Therapeutics Technical and Predictive Indicators
| Risk Adjusted Performance | 0.0281 | |||
| Market Risk Adjusted Performance | (1.14) | |||
| Mean Deviation | 4.54 | |||
| Semi Deviation | 5.27 | |||
| Downside Deviation | 5.46 | |||
| Coefficient Of Variation | 4146.97 | |||
| Standard Deviation | 5.86 | |||
| Variance | 34.33 | |||
| Information Ratio | 0.0122 | |||
| Jensen Alpha | 0.1381 | |||
| Total Risk Alpha | (0.30) | |||
| Sortino Ratio | 0.0131 | |||
| Treynor Ratio | (1.15) | |||
| Maximum Drawdown | 28.43 | |||
| Value At Risk | (8.20) | |||
| Potential Upside | 11.5 | |||
| Downside Variance | 29.76 | |||
| Semi Variance | 27.75 | |||
| Expected Short fall | (4.99) | |||
| Skewness | 0.4052 | |||
| Kurtosis | 0.1815 |
| Risk Adjusted Performance | 0.0281 | |||
| Market Risk Adjusted Performance | (1.14) | |||
| Mean Deviation | 4.54 | |||
| Semi Deviation | 5.27 | |||
| Downside Deviation | 5.46 | |||
| Coefficient Of Variation | 4146.97 | |||
| Standard Deviation | 5.86 | |||
| Variance | 34.33 | |||
| Information Ratio | 0.0122 | |||
| Jensen Alpha | 0.1381 | |||
| Total Risk Alpha | (0.30) | |||
| Sortino Ratio | 0.0131 | |||
| Treynor Ratio | (1.15) | |||
| Maximum Drawdown | 28.43 | |||
| Value At Risk | (8.20) | |||
| Potential Upside | 11.5 | |||
| Downside Variance | 29.76 | |||
| Semi Variance | 27.75 | |||
| Expected Short fall | (4.99) | |||
| Skewness | 0.4052 | |||
| Kurtosis | 0.1815 |
Aligos Therapeutics Bond Ratings
Aligos Therapeutics financial ratings play a critical role in determining how much Aligos Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Aligos Therapeutics' borrowing costs.| Piotroski F Score | 5 | Healthy | View |
| Beneish M Score | (4.45) | Unlikely Manipulator | View |
Aligos Therapeutics Debt to Cash Allocation
Many companies such as Aligos Therapeutics, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Aligos Therapeutics currently holds 8.38 M in liabilities with Debt to Equity (D/E) ratio of 0.1, which may suggest the company is not taking enough advantage from borrowing. Aligos Therapeutics has a current ratio of 5.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Aligos Therapeutics' use of debt, we should always consider it together with its cash and equity.Aligos Therapeutics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Aligos Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Aligos Therapeutics, which in turn will lower the firm's financial flexibility.Aligos Therapeutics Corporate Bonds Issued
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Aligos Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Tools for Aligos Stock
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |